It’s Sunday – and that means another Weekly Pharma News Update from Health and Life. What were the most interesting and important news items of the last week regarding the biopharmaceutical industry?
We were deeply saddened by the tragic news of Sir James Black’s passing. He is known for developing the beta blocker drugs, which are among the most effective cardiac treatments we have.
To honor Sir James Black, we mention this news piece, that beta-blockers may reduce mobility of breast cancer.
Saudia Arabia suspends use of Avandia.
FDA warns that the GlaxoSmithKline Rotarix vaccine was contaminated with a pig virus.
GlaxoSmithKline recruits a L’Oreal executive. Who better knows how to market to consumers and develop brand loyalty?
Shire releases data that shows it is safe to switch to its new Gaucher’s treatment from Genzyme’s treatment. This happens at the same time as Genzyme’s was given an FDA enforcement action over quality issues at a production plant.
Pfizer has been heavily criticized for some of the promotional tactics it has embraced, particularly for neurontin.
A thought-provoking, interesting and well written analysis of the economics behind illicit marketing. If a drug company, after all, can make $1 billion in sales by off-label promotions and only gets a $500 million fine, what is the economically sound choice?
This opinion piece from Forbes talks about Nexium and how it reflects the darker side of health care today.
If you want to get the Weekly Pharma News Update and other important Pharmaceutical analysis, sign up for our PharmaWatch RSS feed.